DISCLAIMER

Our systems have detected that you are using a computer with an IP address located in the USA.
If you are currently not located in the USA, please click “Continue” in order to access our Website.

Local restrictions - provision of cross-border services

Swissquote Bank Ltd (“Swissquote”) is a bank licensed in Switzerland under the supervision of the Swiss Financial Market Supervisory Authority (FINMA). Swissquote is not authorized as a bank or broker by any US authority (such as the CFTC or SEC) neither is it authorized to disseminate offering and solicitation materials for offshore sales of securities and investment services, to make financial promotion or conduct investment or banking activity in the USA whatsoever.

This website may however contain information about services and products that may be considered by US authorities as an invitation or inducement to engage in investment activity having an effect in the USA.

By clicking “Continue”, you confirm that you have read and understood this legal information and that you access the website on your own initiative and without any solicitation from Swissquote.

 

Dossier

Dätwyler

By Bertrand Beauté and Ludovic Chappex
18.12.2017 - 16:00

“Switzerland cannot rest on its laurels”

18.12.2017 - 16:00

AC Immune

By Bertrand Beauté and Ludovic Chappex
18.12.2017 - 15:45

Comet

By Bertrand Beauté and Ludovic Chappex
18.12.2017 - 15:45

Idorsia

By Bertrand Beauté and Ludovic Chappex
18.12.2017 - 15:45

Santhera Pharmaceuticals

By Bertrand Beauté and Ludovic Chappex
18.12.2017 - 15:45

Basilea Pharmaceutica

By Bertrand Beauté and Ludovic Chappex
18.12.2017 - 15:30

GeNeuro

By Bertrand Beauté and Ludovic Chappex
18.12.2017 - 15:30

ObsEva

By Bertrand Beauté and Ludovic Chappex
18.12.2017 - 15:15

“Switzerland isn’t slowing down, but others are catching up”

By Ludovic Chappex
11.12.2017 - 14:30
 
Live chat